vs
CytomX Therapeutics, Inc.（CTMX）与KKR Real Estate Finance Trust Inc.（KREF）财务数据对比。点击上方公司名可切换其他公司
KKR Real Estate Finance Trust Inc.的季度营收约是CytomX Therapeutics, Inc.的1.4倍（$25.8M vs $18.7M），CytomX Therapeutics, Inc.净利率更高（-0.8% vs -101.7%，领先100.9%），CytomX Therapeutics, Inc.同比增速更快（-25.7% vs -26.6%），过去两年CytomX Therapeutics, Inc.的营收复合增速更高（-15.9% vs -18.8%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
KKR房地产金融信托公司是全球投资机构KKR旗下的专业房地产金融平台，主要发起、收购并管理优先担保商业地产贷款组合，抵押物多为美国各地的优质机构级商业地产，通过贷款利息收入为投资者提供稳定的经风险调整后的回报。
CTMX vs KREF — 直观对比
营收规模更大
KREF
是对方的1.4倍
$18.7M
营收增速更快
CTMX
高出0.9%
-26.6%
净利率更高
CTMX
高出100.9%
-101.7%
两年增速更快
CTMX
近两年复合增速
-18.8%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $25.8M |
| 净利润 | $-154.0K | $-26.2M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | -105.1% |
| 净利率 | -0.8% | -101.7% |
| 营收同比 | -25.7% | -26.6% |
| 净利润同比 | 97.6% | -229.6% |
| 每股收益（稀释后） | — | $-0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXKREF
| Q4 25 | — | $25.8M | ||
| Q3 25 | — | $25.3M | ||
| Q2 25 | $18.7M | $30.2M | ||
| Q1 25 | $50.9M | $31.3M | ||
| Q4 24 | $38.1M | $35.1M | ||
| Q3 24 | $33.4M | $37.0M | ||
| Q2 24 | $25.1M | $40.4M | ||
| Q1 24 | $41.5M | $39.1M |
净利润CTMXKREF
| Q4 25 | — | $-26.2M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | $-154.0K | $-29.7M | ||
| Q1 25 | $23.5M | $-4.9M | ||
| Q4 24 | $18.9M | $20.3M | ||
| Q3 24 | $5.7M | $-7.4M | ||
| Q2 24 | $-6.5M | $25.8M | ||
| Q1 24 | $13.8M | $-3.1M |
营业利润率CTMXKREF
| Q4 25 | — | -105.1% | ||
| Q3 25 | — | 50.4% | ||
| Q2 25 | -6.9% | -101.3% | ||
| Q1 25 | 44.4% | -18.3% | ||
| Q4 24 | 46.4% | 55.8% | ||
| Q3 24 | 12.3% | -19.6% | ||
| Q2 24 | -33.7% | 63.3% | ||
| Q1 24 | 28.1% | -8.7% |
净利率CTMXKREF
| Q4 25 | — | -101.7% | ||
| Q3 25 | — | 54.4% | ||
| Q2 25 | -0.8% | -98.5% | ||
| Q1 25 | 46.2% | -15.5% | ||
| Q4 24 | 49.6% | 57.7% | ||
| Q3 24 | 17.2% | -20.0% | ||
| Q2 24 | -26.0% | 63.9% | ||
| Q1 24 | 33.3% | -7.9% |
每股收益（稀释后）CTMXKREF
| Q4 25 | — | $-0.49 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.53 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $-0.19 | ||
| Q2 24 | — | $0.29 | ||
| Q1 24 | — | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $84.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $1.2B |
| 总资产 | $175.1M | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXKREF
| Q4 25 | — | $84.6M | ||
| Q3 25 | — | $204.1M | ||
| Q2 25 | $49.0M | $107.7M | ||
| Q1 25 | $47.6M | $106.4M | ||
| Q4 24 | $38.1M | $104.9M | ||
| Q3 24 | $40.6M | $108.8M | ||
| Q2 24 | $43.2M | $107.2M | ||
| Q1 24 | $36.2M | $106.5M |
股东权益CTMXKREF
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $119.9M | $1.2B | ||
| Q1 25 | $25.0M | $1.3B | ||
| Q4 24 | $-456.0K | $1.3B | ||
| Q3 24 | $-23.5M | $1.4B | ||
| Q2 24 | $-31.2M | $1.4B | ||
| Q1 24 | $-31.7M | $1.4B |
总资产CTMXKREF
| Q4 25 | — | $6.5B | ||
| Q3 25 | — | $6.5B | ||
| Q2 25 | $175.1M | $6.8B | ||
| Q1 25 | $98.5M | $6.6B | ||
| Q4 24 | $120.5M | $6.4B | ||
| Q3 24 | $139.0M | $6.8B | ||
| Q2 24 | $159.2M | $7.1B | ||
| Q1 24 | $184.7M | $7.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $72.3M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | — |
| 自由现金流率自由现金流/营收 | -84.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | — |
8季度趋势，按日历期对齐
经营现金流CTMXKREF
| Q4 25 | — | $72.3M | ||
| Q3 25 | — | $18.5M | ||
| Q2 25 | $-15.8M | $21.1M | ||
| Q1 25 | $-21.0M | $15.9M | ||
| Q4 24 | $-19.9M | $132.6M | ||
| Q3 24 | $-20.7M | $49.1M | ||
| Q2 24 | $-19.5M | $30.6M | ||
| Q1 24 | $-26.0M | $34.5M |
自由现金流CTMXKREF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
自由现金流率CTMXKREF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
资本支出强度CTMXKREF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
现金转化率CTMXKREF
| Q4 25 | — | — | ||
| Q3 25 | — | 1.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | 6.54× | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
KREF
暂无分部数据
